InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod

STOCKHOLM, Feb. 14, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) is today making a presentation with CEO Jenny Sundqvist available in light of the press release issued January

Related Keywords

Sweden ,Stockholm ,Swedish ,Dennis Riedl ,Johan Gil ,Jenny Sundqvist ,Prnewswire Index Pharmaceuticals Holding ,Kindex Pharmaceuticals ,Induction Study ,Dex Pharmaceuticals ,Immunomodulatory Sequences ,Nasdaq First North Growth Market ,Addex Pharma ,Index ,Pharmaceuticals ,Rovides ,Complementary ,Information ,Hase ,Program ,Conclude ,Cobitolimod ,